# Evidence Update: Vitamin D3
## Date: 2026-03-04
## Previous Tier: 2 → Current Tier: 1 (UPGRADED)

### Summary
Vitamin D3 evidence tier upgraded from Tier 2 to Tier 1 based on comprehensive review revealing 20+ meta-analyses across 8+ health domains. Research quality score increased from 89 to 93. Five new high-impact meta-analyses added covering immune function (updated), autoimmune disease, liver health, and glycemic control. Two entirely new benefit domains added (Liver Health, Glycemic Control). Immune function claim refined to reflect deficiency-dependent benefit based on the largest individual participant data meta-analysis ever conducted for vitamin D (64,573 participants).

### New Papers Added (5)

1. **Jolliffe DA et al. (2025)** — "Effect of vitamin D supplementation on acute respiratory infections: updated individual participant data meta-analysis"
   - *Lancet Diabetes & Endocrinology*
   - DOI: 10.1016/S2213-8587(24)00327-5 | PMID: 39993397
   - **Study type:** Individual participant data meta-analysis (46 RCTs, n=64,573)
   - **Key finding:** Universal ARI protection no longer statistically significant (OR 0.93, 95% CI 0.86-1.01). HOWEVER, protection confirmed in vitamin D-deficient individuals (<25 nmol/L) with OR 0.58 (significant). This REFINES the immune benefit claim — it is deficiency-specific, not universal.

2. **El Kababi KA et al. (2025)** — "The Effect of Vitamin D Supplementation on Disease Activity and Inflammatory Markers in SLE Patients: A Systematic Review and Meta-Analysis"
   - *Nutrients*
   - DOI: 10.3390/nu17111917 | PMID: 40944182
   - **Study type:** Systematic review & meta-analysis (21 studies, n=3,177)
   - **Key finding:** Significant improvements in SLEDAI disease activity scores, reduced inflammatory markers (CRP, ESR), and improved complement levels (C3, C4) in SLE patients.

3. **Martinekova K et al. (2025)** — "The effects of vitamin D supplementation on liver function in chronic liver disease: A systematic review and meta-analysis"
   - *Nutrition Reviews*
   - DOI: 10.1093/nutrit/nuaf024 | PMID: 40644459
   - **Study type:** Systematic review & meta-analysis (46 RCTs, n=4,084)
   - **Key finding:** Significant improvements in AST, ALT, albumin, and fibrosis markers across multiple liver pathologies (NAFLD, hepatitis, cirrhosis). First comprehensive MA in this domain.

4. **Bruna-Mejias I et al. (2025)** — "Comprehensive Meta-Analysis on the Effect of Vitamin D Supplementation on Glycemic Control in Type 2 Diabetes"
   - *Nutrients*
   - DOI: 10.3390/nu17091571 | PMID: 41010515
   - **Study type:** Comprehensive meta-analysis (20 RCTs)
   - **Key finding:** Significant improvements in fasting blood glucose, HbA1c, and HOMA-IR in T2DM patients. Establishes glycemic benefit across multiple metabolic parameters.

5. **Zhang J et al. (2025)** — "Dose-stratified network meta-analysis of vitamin D supplementation in T2DM"
   - *Biological Elements and Supplements*
   - DOI: 10.1186/s40360-025-00857-y | PMID: 40616487
   - **Study type:** Network meta-analysis (40 RCTs, dose-stratified)
   - **Key finding:** 2000-4000 IU/day optimal for metabolic benefit in T2DM. Dose-response relationship established with higher doses not showing proportionally greater benefit.

### Evidence Changes

**Tier upgrade: 2 → 1**
- Previous Tier 2 classification was outdated, reflecting an earlier assessment when fewer meta-analyses were available
- Current evidence includes 20+ meta-analyses across 8+ distinct health domains
- Decision tree: Human data (YES) → Hundreds of RCTs → Multiple meta-analyses (YES) → Consistent findings (YES) → Tier 1

**Immune function refinement:**
- Previous claim: Broad immune function support (implied universal benefit)
- Updated claim: "Reduces acute respiratory infection risk in vitamin D-deficient populations"
- Strength downgraded from implied "Strong" to "Moderate" — benefit is real but deficiency-dependent
- This is the most significant qualitative change in this update

**Two new benefit domains added:**
- Liver Health: Based on Martinekova 2025 (46 RCTs, n=4,084) — entirely new domain not previously in database
- Glycemic Control: Based on Bruna-Mejias 2025 (20 RCTs) + Zhang 2025 (40 RCTs) — entirely new domain

**Research quality score: 89 → 93**
- Points gained: +4 from presence of multiple new large meta-analyses, dose-response data, recency of evidence
- All 5 new papers are from 2025, published in high-impact journals

### Recommendation Impact

**Dosage guidance updated:**
- General: 1000-4000 IU/day (unchanged)
- T2DM-specific: 2000-4000 IU/day optimal for metabolic benefit (new, based on Zhang 2025 network MA)
- Benefits apparent by 12 weeks for metabolic outcomes

**Safety profile unchanged:**
- No new safety concerns identified
- Well-established safety at recommended doses

**Target populations expanded:**
- Added: Type 2 diabetes patients, SLE patients, Chronic liver disease patients
- Reinforced: Deficient individuals are the primary beneficiary group across all domains

**Structural fixes in supplements.js:**
- Fixed tier: 2 → 1
- Fixed structural anomaly: evidenceProfile moved inside enhancedCitations (was at same level)
- Replaced generic keyCitations (placeholder "Various" DOI) with 3 real papers
- Added 4 new effectSizes (immune, liver, glycemic, autoimmune)
- Added 3 new mechanismsOfAction
- Added isEnhanced: true at top level

### Files Modified
- `data/enhanced_citations/7_enhanced.js` — 5 new citations, evidenceProfile updated, 2 new benefit domains, 1 new dosage entry
- `data/supplements.js` — ID 7 entry fully updated (tier, rationale, benefits, dosage, populations, mechanisms, effectSizes, keyCitations, enhancedCitations structure)

### Provenance Trail
- `content/provenance/vitamin_d3/search_log.md`
- `content/provenance/vitamin_d3/screening_decisions.md`
- `content/provenance/vitamin_d3/evidence_evaluation.md`
- `content/provenance/vitamin_d3/tier_assignment.md`
- `content/provenance/vitamin_d3/synthesis_notes.md`
